Sandbox Reserved 1482: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 13: | Line 13: | ||
'''1964''': Usual utilisation of concentrated factor VIII to treat hemophilia <ref>Dallman PR & Pool JG. Treatment of hemophilia with factor VIII concentrates. New England Journal of Medicine. 1968 Jan ; 278(4): 199-202. PMID: 5711341 doi: 10.1056/NEJM196801252780406</ref>. | '''1964''': Usual utilisation of concentrated factor VIII to treat hemophilia <ref>Dallman PR & Pool JG. Treatment of hemophilia with factor VIII concentrates. New England Journal of Medicine. 1968 Jan ; 278(4): 199-202. PMID: 5711341 doi: 10.1056/NEJM196801252780406</ref>. | ||
'''1984''': Factor VIII was first characterized by scientists at Genentech <ref name="El">El Khorassani M & Benkirane AN. Le facteur VIII coagulant. Médecine du Maghreb. 1996; 55: 11-13.</ref>. | '''1984''': Factor VIII was first characterized by scientists at Genentech <ref name="El">El Khorassani M & Benkirane AN. Le facteur VIII coagulant. Médecine du Maghreb. 1996; 55: 11-13.</ref>. | ||
'''2017''': Concentrated factor VIII with extended half-life <ref>Ljung RC. Prevention and management of bleeding episodes in children with hemophilia. Pediatric Drugs. 2018 Aug; 1-10. doi https://doi.org/10.1007/s40272-018-0307-z</ref>. | '''2017''': Concentrated factor VIII with extended half-life <ref>Ljung RC. Prevention and management of bleeding episodes in children with hemophilia. Pediatric Drugs. 2018 Aug; 1-10. doi https://doi.org/10.1007/s40272-018-0307-z</ref>. | ||
